Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer.

CD200 PDAC fibroblasts immunotherapy lymphocytes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
02 Nov 2021
Historique:
received: 26 09 2021
revised: 27 10 2021
accepted: 29 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 14 11 2021
Statut: epublish

Résumé

Pancreatic cancer is marked by a desmoplastic tumor microenvironment and low tumor immunogenicity, making it difficult for immunotherapy drugs to improve outcomes for patients. Tumor-infiltrating lymphocytes (TILs) and cancer-associated fibroblasts (CAFs) are seen in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma (PDAC). In this work, we sought to characterize the expression levels and potential prognostic value of TILs (CD4, CD8, and CD20) and CAFs (Thy-1, FAP, and SMA) in a large retrospective cohort of PDAC patients. Additionally, we investigated the expression levels and prognostic significance of CD200, an immunoinhibitory protein that has shown interest as a potential target for immune checkpoint blockade. We measured the expression levels of these seven proteins with multiplexed immunofluorescence staining and quantitative immunofluorescence (QIF). We found CD8 and FAP to be independent predictors of progression-free survival and overall survival. CD200 was found to be heterogeneously expressed in both the tumor and stromal compartments of PDAC, with the majority of patients having positive stromal expression and negative tumor expression. This work demonstrates the potential clinical utility of CD8 and FAP in PDAC patients, and it sheds light on the expression patterns of CD200 in pancreatic cancer as the protein is being tested as a target for immune checkpoint blockade.

Identifiants

pubmed: 34771664
pii: cancers13215501
doi: 10.3390/cancers13215501
pmc: PMC8583434
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Eli Lilly (United States)
ID : GR102387.CC1037.PG00032.PJ000001.DLR2

Références

Cell Rep. 2017 Jul 18;20(3):558-571
pubmed: 28723561
Clin Cancer Res. 2014 Dec 1;20(23):5995-6005
pubmed: 25255793
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Nat Med. 2002 Nov;8(11):1323-7
pubmed: 12389040
JAMA Oncol. 2019 Oct 1;5(10):1431-1438
pubmed: 31318392
Clin Cancer Res. 2021 Mar 1;27(5):1538-1552
pubmed: 33479048
Am J Clin Pathol. 2017 Sep 1;148(3):236-242
pubmed: 28821198
Clin Cancer Res. 2021 Jan 1;27(1):107-119
pubmed: 33046515
Clin Cancer Res. 2020 Jul 15;26(14):3641-3648
pubmed: 32234757
J Surg Oncol. 2021 Mar;123(3):751-759
pubmed: 33595893
Oncoimmunology. 2013 Dec 1;2(12):e26788
pubmed: 24498555
J Natl Cancer Inst. 2020 Nov 1;112(11):1162-1169
pubmed: 31958122
Int J Mol Sci. 2018 Nov 07;19(11):
pubmed: 30405053
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Oncogene. 2018 Aug;37(32):4343-4357
pubmed: 29720723
Nat Commun. 2017 Apr 27;8:15095
pubmed: 28447602
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Sci Rep. 2017 Aug 10;7(1):7848
pubmed: 28798308
Cancers (Basel). 2020 Apr 26;12(5):
pubmed: 32357420
Oncotarget. 2015 Oct 6;6(30):30212-21
pubmed: 26338961
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Nat Commun. 2021 Mar 5;12(1):1453
pubmed: 33674603
Signal Transduct Target Ther. 2020 Apr 17;5(1):38
pubmed: 32300119
J Clin Gastroenterol. 2008 Jan;42(1):86-91
pubmed: 18097296
Cancer Immunol Res. 2019 Jun;7(6):886-895
pubmed: 31043417
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804482
Clin Cancer Res. 2013 Nov 15;19(22):6286-95
pubmed: 23983255
Biotechniques. 2020 Dec;69(6):460-468
pubmed: 32852223
Pancreas. 2004 Jan;28(1):e26-31
pubmed: 14707745
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Mol Carcinog. 2020 Jul;59(7):775-782
pubmed: 32166821
PLoS One. 2013 Sep 13;8(9):e72311
pubmed: 24058443
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499238
Surgery. 2006 Mar;139(3):288-95
pubmed: 16546491
Leukemia. 2007 Mar;21(3):566-8
pubmed: 17252007
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581043
Am J Clin Pathol. 2012 Jan;137(1):93-100
pubmed: 22180482
J Gastrointest Oncol. 2018 Feb;9(1):143-159
pubmed: 29564181
J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15
pubmed: 16368942
J Immunother Cancer. 2014 Dec 16;2(1):46
pubmed: 25598973
PLoS One. 2019 Feb 6;14(2):e0211117
pubmed: 30726287
World J Gastroenterol. 2014 Aug 21;20(31):10802-12
pubmed: 25152583
Clin Cancer Res. 2020 Jul 1;26(13):3420-3430
pubmed: 32161121
Gut. 2014 Nov;63(11):1769-81
pubmed: 24555999
Clin Cancer Res. 2019 Apr 15;25(8):2442-2449
pubmed: 30617133
Ann Gastroenterol Surg. 2018 Jun 22;2(4):274-281
pubmed: 30003190
J Immunother Cancer. 2019 Jul 23;7(1):194
pubmed: 31337426
J Immunother Cancer. 2019 Aug 23;7(1):227
pubmed: 31443741

Auteurs

Tyler MacNeil (T)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Ioannis A Vathiotis (IA)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Saba Shafi (S)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Thazin Nwe Aung (TN)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Jon Zugazagoitia (J)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Aaron M Gruver (AM)

Eli Lilly and Company, Indianapolis, IN 46285, USA.

Kyla Driscoll (K)

Eli Lilly and Company, Indianapolis, IN 46285, USA.

David L Rimm (DL)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Classifications MeSH